About the Company
La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LJPC News
La Jolla Stock Plummets 44% After Disappointing Drug Sales Projections
La Jolla Pharmaceutical Co. () took a pounding Monday, with the stock plunging more than 46% on the heels of disappointing sales projections for its key drug Giapreza. La Jolla's share price fell ...
La Jolla Pharmaceutical
La Jolla Pharmaceuticals' dreams of building a lucrative business from its stable of drugs used in infectious diseases never really paid off, and the company has now sold itself to royalty ...
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline ...
Antimicrobial resistance: Shionogi advocates policy change to address the public health threat
Tetraphase Pharmaceuticals was acquired by La Jolla Pharmaceutical Company. Simply put, the market for antibiotics that address AMR is broken. Shionogi strongly supports the introduction of new ...
Teva Pharmaceutical Swallows Auspex to Strengthen Its Drug Pipeline
Israeli drug company Teva Pharmaceutical Industries is buying ... As a biopharmaceutical company Auspex, of La Jolla, Calif., specializes in applying deuterium chemistry to known molecules to ...
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
SALISBURY, England, March 18, 2024--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage ...
La Jolla centenarian Noreen Haygood celebrates a life of positivity
The longtime La Jolla Woman’s Club member likes to stay active, whether on the tennis court or as a volunteer with the San ...
Lighting on La Jolla Boulevard trees is planned for a test this month in Bird Rock
If La Jolla Boulevard in Bird Rock looks a little brighter in coming weeks, it may be because the Bird Rock Community Council ...
Boydton, United States - Weather forecasts | Maps | News – Yahoo Weather
Night - Mostly clear. Winds variable at 6 to 7 mph (9.7 to 11.3 kph). The overnight low will be 58 °F (14.4 °C). Partly cloudy with a high of 78 °F (25.6 °C) and a 51% chance of precipitation. Winds ...
Diet and Exercise in a Pill Are Real: How Mimetics Work
The National Institutes of Health and the pharmaceutical industry are taking notice ... the Gene Expression Laboratory at the ...
Fail your way to success
The pharmaceutical company Johnson & Johnson announced H3D as ... after which he joined the Scripps Research Institute in La Jolla, California, funded through a Wellcome Trust International Prize ...
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® ...
Loading the latest forecasts...